Hensen J, Kotulla P, Finke R, Bogner U, Badenhoop K, Meinhold H, Schleusener H
J Clin Endocrinol Metab. 1984 Jun;58(6):980-7. doi: 10.1210/jcem-58-6-980.
Several methodological aspects concerning the measurement of thyroid-stimulating antibodies (TSAb) were examined using a 5000-g particulate fraction from human thyroid tissue. TSH displayed maximal stimulation at 32 C. An ATP-regenerating system had no influence at ATP concentrations greater than 0.67 mM. Theophylline did not influence cAMP concentrations in the incubation medium after stimulation with increasing dosages of TSH, suggesting the absence of active phosphodiesterases in the membrane preparations. Sera dialyzed against Tris-HCl were as suitable as immunoglobulin G preparations for determination of TSAb. One hundred and nineteen patients with ophthalmic Graves' disease, 42 of whom were hyperthyroid at the time of study, were investigated for TSH binding-inhibiting antibodies ( TBIAb ) and TSAb. In 76% of these patients, concordance between the presence and absence of both activities was found independent of whether they were untreated, treated, or in remission. When gradations of potency in the two systems were compared, linear regression revealed a correlation coefficient of 0.59. The coefficient correlation increased when TBIAb and TSAb were each determined in a single assay using identical thyroid membrane preparations. In four other patients, both TSAb and TBIAb were measured repeatedly during the course of the disease. In three patients, both activities were parallel, whereas in one patient, dissociation of the two activities was found. The data suggest the presence of antibodies with varying stimulating and binding-inhibiting properties. However, in hyperthyroidism of Graves' disease, both activities usually were present in similar quantities.
使用来自人甲状腺组织的5000g颗粒级分,研究了与促甲状腺素抗体(TSAb)测量有关的几个方法学方面。促甲状腺激素(TSH)在32℃时显示出最大刺激作用。当ATP浓度大于0.67 mM时,ATP再生系统没有影响。在用递增剂量的TSH刺激后,茶碱不影响孵育培养基中的环磷酸腺苷(cAMP)浓度,提示在膜制剂中不存在活性磷酸二酯酶。用Tris-HCl透析的血清与免疫球蛋白G制剂一样适合于TSAb的测定。对119例伴有眼病的格雷夫斯病患者进行了促甲状腺激素结合抑制性抗体(TBIAb)和TSAb检测,其中42例在研究时处于甲状腺功能亢进状态。在这些患者中,76%的患者两种活性的存在与否具有一致性,无论他们是未治疗、已治疗还是处于缓解期。当比较两个系统中效价的分级时,线性回归显示相关系数为0.59。当使用相同的甲状腺膜制剂在单一测定中分别测定TBIAb和TSAb时,相关系数增加。在另外4例患者中,在疾病过程中反复测量了TSAb和TBIAb。在3例患者中,两种活性是平行的,而在1例患者中,发现两种活性分离。这些数据提示存在具有不同刺激和结合抑制特性的抗体。然而,在格雷夫斯病甲状腺功能亢进症中,两种活性通常以相似的量存在。